In this episode, Dr Sonia Anand and Professor Rupert Bauersachs discuss practical perspectives on how vascular surgeons can improve outcomes in patients with symptomatic PAD undergoing peripheral revascularization.

Further details:

• The results of the COMPASS trial can be found here: https://www.nejm.org/doi/full/10.1056/nejmoa1709118

• A subgroup analysis of patients with PAD in the COMPASS trial can be accessed here: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32409-1/fulltext

• A subanalysis of the COMPASS trial investigating the net clinical benefit of dual pathway inhibition is available here: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.046048

• The findings from the VOYAGER PAD trial can be found here: https://www.nejm.org/doi/full/10.1056/nejmoa2000052

• The study investigating the total ischaemic event reduction with rivaroxaban in VOYAGER PAD can be accessed here: https://www.sciencedirect.com/science/article/pii/S0735109721050166

• A meta-analysis of the COMPASS and VOYAGER trials is available here: https://academic.oup.com/eurjpc/advance-article/doi/10.1093/eurjpc/zwab128/6360030

• More information on the effect of concomitant clopidogrel on the efficacy and safety of rivaroxaban and aspirin in VOYAGER can be found here: https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.120.050465

• The CASPAR paper can be accessed here: https://www.jvascsurg.org/article/S0741-5214(10)00981-X/fulltext

• The Dutch BOA trial paper is available here: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(99)07199-8/fulltext

• The summary of product characteristics for rivaroxaban can be found here: https://www.ema.europa.eu/en/documents/product-information/xarelto-epar-product-information_en.pdf

• The summary of product characteristics for clopidogrel can be found here: https://www.medicines.org.uk/emc/product/5288/smpc